gabapentin has been researched along with Abortion, Tubal in 2 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "However, it did reduce postoperative pain, which may prove to be a desired attribute of its use, particularly in cases where postoperative pain may be a greater challenge." | 2.94 | Gabapentin as an adjunct to paracervical block for perioperative pain management for first-trimester uterine aspiration: a randomized controlled trial. ( Cordes, SMD; Cwiak, CA; Ge, L; Gray, BA; Haddad, LB; Hailstorks, TP; Moore, RH, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hailstorks, TP | 1 |
| Cordes, SMD | 1 |
| Cwiak, CA | 1 |
| Gray, BA | 1 |
| Ge, L | 1 |
| Moore, RH | 1 |
| Haddad, LB | 1 |
| Mostacci, B | 1 |
| Poluzzi, E | 1 |
| D'Alessandro, R | 1 |
| Cocchi, G | 1 |
| Tinuper, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gabapentin as an Adjunct to Paracervical Block for Perioperative Pain Management for Surgical Abortion: a Randomized Controlled Trial[NCT02944656] | Phase 4 | 114 participants (Actual) | Interventional | 2016-12-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"During the Postoperative Day 1 phone call, participants self reported how much they experienced moderate pain in the last 24 hours where 10 = none of the time and 0 = all of the time. Moderate pain was defined according to the perception of each participant." (NCT02944656)
Timeframe: Postoperative Day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin Group | 5.2 |
| Placebo Group | 5.2 |
During the Postoperative Day 1 phone call, participants self reported how much they experienced nausea or vomiting in the last 24 hours where 10 = none of the time and 0 = all of the time. Nausea and vomiting were self-reported together as a single outcome. (NCT02944656)
Timeframe: Postoperative Day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin Group | 2.3 |
| Placebo Group | 3.2 |
The number of participants reporting filling and using the prescription for ibuprofen postoperatively. During the follow-up phone call on the day after the procedure, participants were asked whether or not they filled the pain medication prescription and if they took any of the medication. (NCT02944656)
Timeframe: Postoperative Day 1
| Intervention | Participants (Count of Participants) |
|---|---|
| Gabapentin Group | 24 |
| Placebo Group | 27 |
"During the Postoperative Day 1 phone call, participants self reported how much they experienced severe pain in the last 24 hours where 10 = none of the time and 0 = all of the time. Severe pain was defined according to the perception of each participant." (NCT02944656)
Timeframe: Postoperative Day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin Group | 3.5 |
| Placebo Group | 3.2 |
"Participants reported how much anxiety they were currently experiencing on a 100-point scale where No Anxiety is scored as 0 and Extremely Anxious is scored as 100. Anxiety is reported for the time periods of immediately prior to the procedure, 10 minutes after the procedure, and 30 minutes after the procedure." (NCT02944656)
Timeframe: Pre-procedure through post-procedure on Study Day 1
| Intervention | score on a scale (Median) | ||
|---|---|---|---|
| Prior to procedure | 10 minutes post-procedure | 30 minutes post-procedure | |
| Gabapentin Group | 66 | 14 | 4 |
| Placebo Group | 72 | 17 | 2 |
"The primary outcome measure is a pain score using a 100-mm visual analog scale (VAS) measured intraoperatively at time of evacuation. No pain is scored as 0 and worst pain imaginable is scored as 100." (NCT02944656)
Timeframe: During the procedure on Study Day 1
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Paracervical block | Dilation | Aspiration | |
| Gabapentin Group | 63.79 | 64.58 | 67.77 |
| Placebo Group | 62.21 | 66.12 | 71.06 |
"Nausea level was measured using a 100-mm visual analog scale (VAS) to log the change in nausea levels between the study arms. No nausea is reported as 0 while worst nausea I have ever felt is reported at 100. Nausea was reported immediately prior to the procedure, 10 minutes following the procedure, and 30 minutes following the procedure." (NCT02944656)
Timeframe: Pre-procedure through post-procedure on Study Day 1
| Intervention | score on a scale (Median) | ||
|---|---|---|---|
| Prior to procedure | 10 minutes post-procedure | 30 minutes post-procedure | |
| Gabapentin Group | 26 | 1 | 0 |
| Placebo Group | 26 | 12 | 5 |
"Pain level at a variety of time points will be measured using a 100-mm visual analog scale (VAS) to log the change in pain levels between the study arms. No pain is scored as 0 and worst pain imaginable is scored as 100. Pain will be assessed immediately prior to the procedure, at completion of the procedure (removal of the speculum), 10 minutes following the procedure, and 30 minutes following the procedure (at discharge)." (NCT02944656)
Timeframe: Pre-procedure through post-procedure on Study Day 1
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Prior to procedure | Speculum removal | 10 minutes post-procedure | 30 minutes post-procedure | |
| Gabapentin Group | 20.76 | 44.10 | 30.64 | 20.89 |
| Placebo Group | 22.48 | 47.61 | 43.68 | 31.65 |
Participants reported if they vomited during the perioperative period to assess changes in vomiting incidences between the study arms. Vomiting is reported for the time periods of immediately prior to the procedure, 10 minutes following the procedure, and 30 minutes following the procedure. (NCT02944656)
Timeframe: Pre-procedure through post-procedure on Study Day 1
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Prior to procedure | 10 minutes post-procedure | 30 minutes post-procedure | |
| Gabapentin Group | 4 | 5 | 5 |
| Placebo Group | 7 | 2 | 5 |
Participants were asked if they experienced dizziness, lack of muscle control, sleepiness or drowsiness, weakness or lack of energy, headache, or visual changes. (NCT02944656)
Timeframe: 10 and 30 minutes post procedure on Study Day 1
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dizziness 10 minutes post-procedure | Dizziness 30 minutes post-procedure | Lack of muscle control 10 minutes post-procedure | Lack of muscle control 30 minutes post-procedure | Sleepiness/drowsiness 10 minutes post-procedure | Sleepiness/drowsiness 30 minutes post-procedure | Weakness 10 minutes post-procedure | Weakness 30 minutes post-procedure | Headache 10 minutes post-procedure | Headache 30 minutes post-procedure | Vision changes 10 minutes post-procedure | Vision changes 30 minutes post-procedure | |
| Gabapentin Group | 27 | 19 | 9 | 5 | 38 | 30 | 33 | 20 | 5 | 4 | 9 | 3 |
| Placebo Group | 23 | 15 | 9 | 10 | 34 | 29 | 34 | 28 | 4 | 4 | 11 | 5 |
1 trial available for gabapentin and Abortion, Tubal
| Article | Year |
|---|---|
Gabapentin as an adjunct to paracervical block for perioperative pain management for first-trimester uterine aspiration: a randomized controlled trial.
Topics: Abortion, Induced; Abortion, Spontaneous; Adult; Analgesics; Anesthesia, Local; Anesthesia, Obstetri | 2020 |
1 other study available for gabapentin and Abortion, Tubal
| Article | Year |
|---|---|
Adverse pregnancy outcomes in women exposed to gabapentin and pregabalin: data from a population-based study.
Topics: Abortion, Induced; Abortion, Spontaneous; Adult; Anticonvulsants; Congenital Abnormalities; Female; | 2018 |